Aurobindo Pharma Limited announced the incorporation of ‘Avogent Lifesciences Private Limited’ as a new wholly owned subsidiary. This move is by its subsidiary, Apitoria Pharma Private Limited, and aims to support manufacturing and marketing operations in India and internationally. The new entity was incorporated on August 31, 2026, with an initial share capital of ₹5 crore. This expansion is part of the company’s strategic growth initiatives.
New Subsidiary Established for Growth
Aurobindo Pharma Limited has disclosed the incorporation of a new wholly owned subsidiary, named Avogent Lifesciences Private Limited. This new entity has been established by Apitoria Pharma Private Limited, which is itself a wholly owned subsidiary of Aurobindo Pharma Limited. The primary objective of Avogent Lifesciences Private Limited is to engage in manufacturing and marketing operations, both within India and in overseas markets, aligning with the company’s broader expansion strategies.
Key Details of the New Entity
Avogent Lifesciences Private Limited was incorporated on August 31, 2026, in India. The company’s initial share capital comprises 50,00,000 equity shares of ₹10 each, totaling an investment of ₹5 crore. This investment represents a 100% subscription to the share capital in cash by the parent subsidiary. As the company is newly incorporated, its turnover history is not applicable, and no governmental or regulatory approvals were required for its establishment.
Strategic Rationale
The incorporation of this subsidiary is a strategic step to facilitate the company’s plans for global manufacturing and marketing presence. It allows for dedicated focus on specific business segments or geographical expansions. The transaction falls under related party transactions as it involves a subsidiary of a subsidiary, but it is conducted at ‘arms-length’. Promoters and the promoter group of Aurobindo Pharma Limited have no interest in this specific transaction.
Source: BSE
